CTRI/2022/02/040285已完成4 期
A prospective multicentre phase-IV clinical study to evaluate the safety of single intramuscular dose of Biological E’s typhoid conjugate vaccine in 6 months to 45 years old participants and its impact on measles immunogenicity when co-administered with licensed Measles-Rubella (MR) vaccine in a subset of 9-12 months old infants. - None
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 1,252
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy subjects of either gender between =6 months to <45 years of age at the time of vaccination
- •2. Subject or Subject’s Parent(s) or LAR, who, after the nature of the study has been explained to them, have given written consent according to local regulatory requirements.
- •3. Subject or Subject’s Parent(s) or LAR’s ability to understand information relevant to participation in the study and abide with the requirements of the subject diary and other study procedures;
- •4. Individuals in good health as determined by the outcome of medical history, physical examination based on clinical judgment of the investigator.
- •5. Negative to urine pregnancy test for female subjects of childbearing potential. Female of childbearing potential is defined as a pre-menopausal female capable of becoming pregnant. This does not include females who meet any of the following conditions: (1) menopause at least 2 years earlier, (2) tubal ligation at least 1 year earlier, or (3) total hysterectomy.
排除标准
- •1. Individuals who have previously received any vaccines against typhoid fever (either oral live attenuated or injectable vaccines);
- •I. Subjects between 9-12 months, who have previously received measles containing vaccine such as Measles/MR/MMR (only for Sub group 1 & 2 under age subset 1).
- •II. However, any subject previously vaccinated with Measles containing vaccine can be enrolled in Sub group 3 only under age subset 1.).
- •2. Individuals with body temperature =100.4°F (=38.0°C) within 3 days of intended study immunization;
- •3. Individuals with any serious chronic or progressive disease according to judgment of the investigator (e.g., neurological, neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease);
- •4. Subject or Subject’s Parent(s) or LAR unwillingness or inability to understand and follow required study procedures, keep appointments, or are planning to relocate during the study period;
- •5. Individuals with history of any illness or any laboratory abnormality that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study;
- •6. Subject with a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time or history of receipt of anti-coagulants in the past 3 weeks;
- •7. History of allergy or allergic reaction to any vaccine-related component;
- •8. Individuals participating in any other clinical trial within 30 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study;
- •9. Women who are pregnant or breast-feeding or of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study. Female of childbearing potential or age is defined as a pre-menopausal female capable of becoming pregnant. This does not include females who meet any of the following conditions: (1) menopause at least 2 years earlier, (2) tubal ligation at least 1 year earlier, or (3) total hysterectomy.
- •10. Any other reason that in the opinion of the investigator may interfere with the evaluation required by the study objectives.
研究者
相似试验
进行中（未招募）
4 期
A clinical study to assess the safety of BEs Pneumococcal conjugate vaccine when administered in a three dose schedule.CTRI/2023/09/057894Biological ELimited
招募中
4 期
Phase IV study to assess the safety, efficacy and immunogenicity of MJ Pharma-BIOSULIN�® 30:70CTRI/2020/03/024054M J Biopharm Private Limited
已完成
4 期
Phase -IV study to check the safety of fixed dose combination of dapagliflozin and saxagliptin in Indian Type 2 Diabetes Mellitus patientsCTRI/2021/02/031471AstraZeneca Pharma India Ltd196
招募中
4 期
This research study will be conducted to understand the side effects and effectiveness of the already marketed medicine named as SomatoRel™ (recombinant human growth hormone) in growth hormone deficient children (child is significantly shorter than children his or her age)CTRI/2020/07/026292Reliance Life Sciences Pvt Ltd RLS
已完成
4 期
The purpose of this research study is to evaluate the safety and effectiveness profile of the medicine named as EtanerRelTM in patients with different type of arthritis (joint pain)CTRI/2021/06/034073Reliance Life Sciences Pvt Ltd230